Cholesterol-lowering therapy: Is there really a controversy?

Annals of Pharmacotherapy

Volumn 30, Issue 5, 1996, Pages 539-542

  Jungniekel, Paul W ^a  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ATHEROGENESIS; CHOLESTEROL METABOLISM; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; NOTE; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE; THROMBOEMBOLISM;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; PRIMARY PREVENTION;

EID: 0030005728     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000520     Document Type: Article

References (33)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Canner PL, Berge KG, Wenger NK, Stander J, Freidman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
3. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial, I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
6. Philbin EF, Pearson TA. How does lipid-lowering therapy rapidly reduce ischemic events? J Myocaid Ischemia 1994;6(10):13-8.
7. Levine GN, Keaney JF Jr, Vita JA Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 1993;269:3015-23.
9. Geurian KL. The cholesterol controversy Ann Pharmacother 1996;30:495-500.
10. Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Manttari M, Manninen V. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease: an ancillary study in Helsinki Heart Study frame population. Ann Med 1993;25:41-5.
11. Superko HR, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-69.
12. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
13. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
14. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart JD, Smith LDR, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.
15. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
16. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993;341:1496-500.
17. Treasure CB, Klein JL, Weintraub WS, Talley ID, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
18. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
19. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin AF, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results, I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
20. Product information. Lopid (gemfibrozil). Morris Plains, NJ: Parke Davis, Division of Warner-Lambert, 1994.
21. Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Lonnqvist J, Ehnholm C. Serum cholesterol concentration and mortality from accidents, suicide, and other violent causes. BMJ 1994;309:445-7.
22. Weidner G, Connor SL, Hollis JF, Connor WE. Improvements in hostility and depression in relation to dietary change and cholesterol lowering: the Family Heart Study. Ann Intern Med 1992;117:820-3.
23. Eckernas SA, Roos BE, Kvidal P, Eriksson LO, Block GA, Neafus RP, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG-CoA reductase inhibitors in patients with primary moderate hypercholesterolemia. Br J Clin Pharmacol 1993;35:284-9.
24. Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 1991;50:730-7.
25. Wysowski DK, Gross TP. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. Arch Intern Med 1990;150:2169-72.
26. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14.
27. Committee of Principle Investigators. A cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 1978;40:1069-118.
28. Dalen JE, Dalton WS. Does lowering cholesterol cause cancer? JAMA 1996;275:67-9.
29. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60.
30. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
31. Law MR, Thompson SG, Wald NJ. Assessing possible hazards or reducing serum cholesterol BMJ 1994;308:373-9.
32. Adkins D, Psaty BM, Koepsell TD, Longstreth WT, Larson EB. Cholesterol reduction and the risk of stroke in men: a meta-analysis of randomized, controlled trials. Ann Intern Med 1993;119:136-45.
33. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program Circulation 1995;92:2419-25.